The Yes-associated protein YAP is a downstream effector of the Hippo pathway of cell cycle control which plays important roles in tumorigenesis. Hippo-mediated phosphorylation YAP, mainly at S127, inactivates YAP function. In this study, we define a mechanism for positive regulation of YAP activity that is critical for its oncogenic function. Specifically, we found that YAP is phosphorylated in vitro and in vivo by the cell cycle kinase CDK1 at T119, S289, and S367 during G2/M phase of the cell cycle.
YAP promotes tumorigenesis in several types of cancer, including hepatocellular carcinoma (HCC) (13) and skin cancer (14) . It is not surprising that YAP is amplified or overexpressed/hyperactivated in many types of human cancer (13, 15) . Accordingly, genetic ablation of upstream tumor suppressors (for example, Mst1/2, WW45, and Mob1a/1b) in mice also leads to formation of many types of tumors including HCC (16) (17) (18) (19) (20) .
Although extensive studies have demonstrated the important roles for the Hippo pathway in tumorigenesis, the underlying mechanisms are still unclear. Interestingly, recent studies demonstrated that several key members of the Hippo pathway, such as Mst1/2, Lats1/2, WW45, Mob1 are involved in regulating mitosis (21) . Aberration of mitosis often causes genome instability/aneuploidy and subsequent tumor formation.
Thus, the Hippo pathway may contribute to cancer development by regulating mitosisrelated events.
We recently reported that KIBRA (an upstream regulator of the Hippo pathway) is growth mediator of the Hippo pathway, is regulated during mitosis. We show that YAP is also hyperphosphorylated during G2/M phase. We further characterized the phosphorylation sites, the corresponding kinase, and the functional significance of the phosphorylation. Our data reveal a new layer of regulation for YAP activity, implicating that YAP exerts its oncogenic function through dysregulation of mitosis.
Materials and Methods

Expression constructs
YAP-S381A, YAP with mutations in the WW domains, and YAP-5SA plasmids were purchased from Addgene. pcDNA-YAP (no tag) expression constructs have been described (13). To make HA-tagged human YAP, full-length YAP cDNA (IMAGE clone 5747370, contains 2 WW domains and 504 amino acids) was subcloned into the pcDNA3.1+HA vector (25). To make the retroviral-mediated YAP expression construct, the above cDNA was cloned into MaRX TM IV vector (25). Point mutations were generated by the QuickChange Site-Directed PCR mutagenesis kit (Stratagene) and verified by sequencing.
Cell culture and transfection
Research. Author Manuscript Published OnlineFirst on October 7, 2013; DOI: 10.1158/0008-5472. CAN-13-2049 sequentially isolated for fragmentation in the linear ion trap by collision-induced dissociation. The capillary was maintained at 200°C, the spray voltage was kept at 2.3 kV. DeconMSn was used to determine and refine the monoisotopic mass and charge state of parent ions from the LTQ-Velos raw data, and to create a peak list of these ions in .mgf format. The ".mgf" files were searched against the human International Protein Index (IPI) protein sequence database (Version 3.52) which contained the normal IPI human proteins, commonly observed contaminants and the reverse sequences of all proteins with the OMSSA search engine (version 2.1.9, NCBI) (28). In the database search, carbamidomethylation of cysteine was set as the fixed modification. Oxidation of methionine, phosphorylation of serine, threonine and tyrosine were set as the variable modifications. The precursor tolerance was set as 1.5 Da and MS2 tolerance was 0.5
Da. E-value cut-off was set at 0.1. The false discovery rate (FDR) was made 1% by filtering on the E-value of all forward and reversed peptide identifications. The spectra were manually checked.
(treated with DMSO or Taxol) in kinase buffer (23) in the presence of 5 µCi γ-32 P-ATP (3000 Ci/mmol, PerkinElmer). MEK1, ERK1, and p38α active kinases were purchased from SignalChem. Myelin basic protein (MBP) (Sigma) was used for positive control.
The samples were resolved by SDS-PAGE, transferred onto PVDF (Millipore) and visualized by autoradiography followed by Western blotting or detected by phosphospecific antibodies.
Antibodies
The YAP antibodies from Abnova (H00010413-M01) and Abcam (52771) were used for immunoprecipitation of endogenous YAP and for Western blotting, respectively throughout the study. Rabbit polyclonal phospho-specific antibodies against YAP S367, S289, and T119 were generated and purified by AbMart. HA antibodies were from Sigma. Anti-β-actin, anti-ERK1/2, and anti-cyclin B antibodies were from Santa Cruz Biotechnology. Anti-Aurora-A, anti-glutathione S-transferase (GST), anti-His, anti-Mst1, anti-Mst2, anti-Lats1, and anti-Lats2 antibodies were from Bethyl Laboratories. Antiphospho-Aurora-A,B,C, anti-phospho-S10 H3, anti-phospho-T202/Y204 ERK1/2, antiphospho-S127 YAP, anti-phospho-T180/Y182 p38, anti-phospho-c-Jun, anti-phosphoMst1/2, anti-phospho-Lats1/2, anti-phospho-S345 Chk1, anti-p38, anti-WW45, anti-TAZ, anti-NF2, anti-Mob1, and anti-Cdc2 antibodies were from Cell Signaling Technology.
Anti-Plk1 and anti-phospho-T210 Plk1 antibodies were obtained from Biolegend. Anti-α-tubulin (Abcam), anti-β-tubulin (Sigma), anti-γ-tubulin (Biolegend) antibodies were used for immunofluorescence staining.
Immunoprecipitation, Western blot analysis, and lambda phosphatase treatment
Immunoprecipitation, Western blotting, and lambda phosphatase treatment assays were done as previously described (23) .
Immunofluorescence staining and confocal microscopy
Cell fixation, permeabilization, fluorescence staining, and microscopy were done as previously described (22) . For peptide blocking, a protocol from Abcam website was used. Briefly, the phospho-YAP antibodies were first neutralized by an excess of immunizing (phosphorylated) peptides (1 µg/ml for 1 h at room temperature). The antibody (containing the phospho-peptide) was then used for staining in parallel with staining using antibodies with no peptide or non-phospho-peptide.
Colony formation, cell migration, and invasion assays
Research. Colony formation assays in soft agar were performed as described (13). In vitro analysis of invasion and migration was assessed using the BioCoat invasion system (BD Biosciences) and Transwell system (Corning), respectively, according to the manufacturer's instructions. The invasive and migratory cells were stained with ProLong® Gold Antifade Reagent with DAPI. The relative invading and migrating rate were calculated by the number of cells invading and migrating through the membrane, divided by the number of cells that invaded and migrated in the control group.
Statistical analysis
Statistical significance was performed using a two-tailed, unpaired Student's t-test.
Results
YAP is phosphorylated during anti-mitotic drug-induced G2/M arrest
To further explore whether other members of the Hippo pathway are regulated during mitosis, we treated HeLa cells with Taxol or nocodazole (both agents arrest cells in G2/M) and systematically examined the responses of the Hippo pathway during G2/M arrest. As shown in Figure 1A , the most prominent change we observed was the dramatic mobility up-shift of YAP and, to a lesser extent, of TAZ. The phosphorylation level of YAP at S127 (the major phosphorylation site regulated by the Hippo pathway) was not altered, suggesting that the mobility shift of YAP was likely not due to the phosphorylation at S127. Taxol or nocodazole treatment did not cause any evident change in the expression levels for NF2, Mst1/2, WW45, Mob1, or in the activity of Mst1/2 and Lats1/2 revealed by phospho-antibodies (Fig. 1A) . Consistent with previous reports, we detected a mobility up-shift of Lats1 (due to mitotic phosphorylation) (29, 30) and a significant increase of Lats2 expression (31) during Taxol or nocodazole treatment (Fig. 1A) . The mobility up-shift of YAP was also evident in breast (MCF-7, T47D, and MDA-MB-231), colon (HCT-116) and lung (H1299 and H2227) cancer cell lines during Taxol-arrested mitosis (Fig. 1B) . The shift was detectable as early as 4 h after 100 nM Taxol treatment, and only 10 nM of Taxol (for a 16 h treatment) was sufficient to induce the shift in HeLa cells (Fig. 1C) . Taken together, YAP mobility is significantly retarded during anti-mitotic drug-induced G2/M arrest.
YAP is a phospho-protein whose mobility is retarded on SDS-polyacrylamide gels when phosphorylated (10, 13). Lambda phosphatase treatment completely converted all slowmigrating bands to fast-migrating bands, indicating that the mobility shift of YAP during G2/M is caused by phosphorylation (Fig. 1D) phosphorylation is specific to mitosis, we collected mitotic cells by mechanical shake-off from Taxol-treated cells. As shown in Figure 2A , mitotic cells expressed exclusively phosphorylated YAP while YAP is not phosphorylated/shifted in attached non-mitotic cells, suggesting that YAP phosphorylation is specifically associated with G2/M cell cycle arrest.
Previous reports showed that YAP was phosphorylated by c-Abl, p38, and JNK kinases in response to DNA damage (32) (33) (34) . We further explored whether DNA-damaging agents can cause such a mobility shift of YAP. As shown in Figure 2B , in contrast to YAP shift during mitosis, treatment with doxorubicin, etoposide, UV or ionizing radiation (IR) failed to cause any obvious change on YAP mobility. Increased activity of Chk1 revealed by phospho-S345 antibody indicated these treatments were effective. These data further suggest that the mobility shift/phosphorylation of YAP is a specific response during cell cycle G2/M.
Identification of the corresponding kinase(s) for YAP phosphorylation
Upon treatment of anti-mitotic agents, several mitotic kinases, including Aurora and Plk1, are activated during mitosis (35) . Inhibitors for these kinases are widely used. CDK1 is a master regulator of cell cycle and is activated during normal and drugarrested G2/M (35, 38) . JNK1/2 kinases are also activated upon Taxol treatment ( kinases are responsible for YAP phosphorylation. As shown in Figure 2C (left panel), both RO3306 (a CDK1 inhibitor) and SP600125 (a JNK1/2 inhibitor) completely reverted the mobility shift of YAP. These drugs are known to induce mitotic exit as shown by the complete loss of phospho-Aurora and degradation of cyclin B. We treated the cells with MG132 along with RO3306 or SP600125 to prevent cyclin B degradation and cells exiting from mitosis. Under these conditions, RO3306, but not SP600125, was still able to completely inhibit YAP phosphorylation (Fig. 2C ). In the presence of RO3306, YAP was no longer phosphorylated even when JNK1/2 kinases were strongly activated ( Fig.   2C , lanes 3 and 7), suggesting that CDK1, but not JNK1/2 kinases, is likely to be responsible for YAP phosphorylation. Furthermore, another CDK1 inhibitor (roscovitine) also completely inhibited YAP phosphorylation (Fig. 2D ). Taken together, these data strongly suggest that YAP phosphorylation induced by Taxol treatment is CDK1 dependent and is independent of JNK1/2 kinases.
CDK1 phosphorylates YAP in vitro
To determine whether CDK1 kinase can directly phosphorylate YAP, we performed in vitro kinase assays with His-tagged YAP as substrates. Figure 2E shows that Taxoltreated mitotic lysates robustly phosphorylated YAP and that CDK1 depletion greatly 3A ) of CDK1-phosphorylation sites (39) . Interestingly, all these three sites have been identified as mitotic phosphorylation sites from large scale proteomic studies (40, 41) .
We next examined whether these sites affect the mobility of YAP during Taxol treatment. YAP mutated S367 or T119 (to alanine) had a reduced mobility shift when compared to wild-type YAP (Fig. 3B , compare lanes 6, 4 to lane 2). S289A mutation had Author Manuscript Published OnlineFirst on October 7, 2013; DOI: 10.1158/0008-5472.CAN-13-2049 no effect on YAP mobility induced by Taxol (Fig. 3B, compare lanes 8 to 2) . No further decrease on YAP mobility was observed when T119 and S289, or S289 and S367 were mutated to non-phosphorylatable alanine (Fig. 3B , compare lanes 10 to 6; lanes 14 to 4). However, double mutation of T119A and S367A or triple mutation of all three sites largely abolished the mobility shift of YAP, suggesting that T119 and S367 are the main sites responsible for mobility shift of YAP upon Taxol treatment (Fig. 3B ).
For comparison, we also tested whether some other known phosphorylation or binding sites are involved in the YAP mobility shift induced by Taxol treatment. Mutating the Hippo phosphorylation sites (S127, S381, 5SA: S381A/S164A/S127A/S109A/S61A) (10, 12, 13) or TEAD binding site (S94) (5) or the c-Abl phosphorylation site (Y407) (33) did not affect the YAP shift induced by Taxol in HEK293T cells (Supplemental Fig.   S2D ). The WW domain mutations (W199A/P202A and/or W258/P261A) did not affect the Taxol-induced YAP shift either (data not shown). Together, our data identified novel phosphorylation of YAP during Taxol-arrested G2/M. We have generated phospho-specific antibodies against T119, S289, and S367. Using these antibodies we demonstrated that CDK1 robustly phosphorylated YAP at T119, S289 and at S367 as well in vitro (Fig. 3C) . Addition of RO3306 abolished the phosphorylation (Fig. 3C) . To explore whether T119 and S289 are also phosphorylated within cells during Taxol-induced G2/M arrest, we transfected YAP or corresponding non-phosphorylatable mutants into cells, treated the cells with Taxol, and determined levels of phosphorylation by phospho-antibodies. Taxol treatment significantly increased the phosphorylation of T119 and S289, and the signal was abolished by mutating T119 or S289 to alanine (Fig. 3D) . Taxol treatment also significantly increased the phosphorylation of T119 and S289 in immunoprecipitated endogenous YAP (Fig. 3E ).
As expected, no signal was detected in control (IgG) immunoprecipitates, suggesting that these antibodies specifically recognize phosphorylated YAP. Lambda phosphatase treatment completely abolished the signal, further confirming the specificity of the phospho-specific antibodies (Fig. 3F) . Using inhibitors for CDK1 kinase, we demonstrated that phosphorylation of YAP T119 and S289 is CDK1 kinase dependent (Fig. 3F) . Taken together, these results indicate that YAP is phosphorylated at T119 and S289 in cells during anti-mitotic drug-induced G2/M arrest in a CDK1-dependent manner.
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Phosphorylation of YAP occurs in cells during normal mitosis
To determine whether mitotic phosphorylation of YAP occurs during unperturbed/normal mitosis, we collected samples from a double thymidine block and release (22) and determined the phospho-levels of YAP during different cell-cycle phases. Figure 4A shows that phosphorylated YAP was readily detected in cells 8-10 hours being released from double thymidine block, which is coincident with increased levels of cyclin B and phospho-H3 S10 (both of which are mitotic markers). The signal was diminished when cells exit mitosis (Fig. 4A, lane 4) . These data strongly suggest that YAP is phosphorylated at T119 and S289 during normal mitosis.
To further investigate the dynamics of YAP phosphorylation in cells, we performed immunofluoresence microscopy with these phospho-specific antibodies. A strong signal was detected in nocodazole-arrested prometaphase cells for both antibodies against S289 and T119 (Supplemental Fig. S3A , B, top panels, red arrows). Very low or no signal was detected in interphase cells (Supplemental Fig. S3A, B, yellow arrows) .
Importantly, phosphopeptide-, but not non-phosphopeptide-, incubation completely blocked the signal, suggesting that these antibodies specifically detect phosphorylated YAP (Supplemental Fig. S3A, B, low panels) . The specificity of the antibodies was 
further confirmed by siRNA knockdown of YAP (Supplemental Fig. S3C, D) . We found that the p-YAP-S289 signal was clearly increased in prophase and peaked in prometaphase/metaphase. The signal was then weakened during metaphase to anaphase transition and further diminished in telophase and cytokinesis (Fig. 4B) .
Similar staining patterns were generated with p-YAP-T119 antibody staining ( Fig. 4C;   Supplemental Fig. S4) . These data further demonstrate that mitotic phosphorylation of YAP occurs dynamically in cells. Addition of RO3306 or roscovitine largely abolished the signals detected by p-YAP S289 and T119 antibodies in mitotic cells, further indicating that the phosphorylation is CDK1 dependent (Fig. 4D) .
Phospho-mimetic YAP induces mitotic abnormalities in immortalized cells
Some of the Hippo components regulate mitotic events including chromosome alignment, centrosome duplication, and microtubule dynamics (21) . We next examined whether YAP or its phosphorylation is able to trigger mitotic defects. The immortalized epithelial cell line MCF10A stably expressing vector, YAP, and YAP3D (a phosphomimetic mutant) were used for this purpose (Fig. 5A) . As expected, immunofluoresence staining with α-tubulin and γ-tubulin showed normal microtubule/spindle formation and centrosome number during mitosis in control cells (Fig. 5B) 
YAP is not sufficient to cause significant mitotic defects in MCF10A cells (Fig. 5D-F) . In contrast, mitotic abnormalities were detected in a significant higher percentage of cells expressing YAP3D (3-4 fold) . There is a threefold increase of number of YAP3D-expressing cells with disorganization of microtubules and formation of multipolar spindles when compared with control cells (Fig. 5B, D) . We also found the percentage of cells with more than 2 centrosomes (γ-tubulin staining) significantly increased in YAP3D-expressing cells (Fig. 5B, E) . As expected, massive chromosome misalignment, chromosome lagging, and chromosome missegregation were observed in about 25% of YAP3D-expressing cells (Fig. 5B, C, F) . These data suggest that ectopic expression of phospho-mimetic YAP, but not wild-type YAP, is sufficient to trigger mitotic abnormalities in immortalized epithelial cells.
Mitotic phosphorylation of YAP is required for cellular transformation
Overexpression of YAP transforms MCF10A cells (15) . We further examined the biological significance of mitotic phosphorylation of YAP using these cell lines stably expressing YAP or YAP mutants (Fig. 6A) . MCF10A cells expressing YAP-S127A formed colonies in soft agar, however, MCF10A-YAP4A (S127A/T119A/S289A/S367A) cells failed to produce any obvious colonies (Fig. 6B, C) . YAP3D overexpression is not sufficient to stimulate anchorage-independent growth in soft agar (data not shown). YAP or YAP-3A (T119A/S289A/S367A) overexpression failed to produce colonies in soft agar (Fig. 6B and data not shown) . Together, these data strongly suggest that mitotic phosphorylation is required for YAP-mediated cellular transformation in MCF10A cells.
Mitotic phosphorylation of YAP promotes cell migration and invasion
Recent reports showed that YAP/YAP-S127A also promotes migration and invasion in vitro (42) and metastasis in vivo (43) . Interestingly, centrosome amplification has been correlated with cancer invasiveness and enhances migration and invasion of malignant cells via modulation of microtubule cytoskeleton (44) . We therefore tested whether mitotic phosphorylation of YAP is involved in cell motility. As expected, ectopic expression of YAP and YAP-S127A increased migration (Fig. 6D) and invasion (Fig. 6E) of MCF10A cells. Mutating CDK1-mediated phosphorylation sites to alanine (YAP-4A) dramatically suppressed YAP-S127A-mediated migration (Fig. 6D) and invasion (Fig.   6E ). Interestingly, cells expressing YAP3D possess much higher migration and invasion activity than cells expressing wild-type YAP (Fig. 6D, E) . These data suggest that mitotic phosphorylation of YAP promotes cell motility in immortalized epithelial cells. The above observations indicate that elimination of phosphorylation of YAP by CDK1 inhibitors reduces YAP, but not YAP3D, -mediated cell motility. Indeed, addition of RO3306 almost completely suppressed YAP-S127A-driven migration (Fig. 6F) and invasion (Fig. 6G) . Importantly, YAP3D-mediated migration and invasion was not affected by the presence of RO3306 (Fig. 6F, G) . Collectively, these data strongly indicate that YAP promotes migration and invasion in a CDK1-phosphorylation dependent manner. Importantly, YAP-3D (a phosphorylation mimetic mutant), but not wild-type YAP, drives mitotic defects (Fig. 5) . Thus, our data suggest there may be a positive layer of regulation for YAP activity during tumorigenesis, and highlight a previously unrevealed mechanism through which YAP exerts its oncogenic function (Fig. 6H) . Interestingly, increased CDK1 activity also promotes defects in various mitosis-related processes and aneuploidy, and CDK1 overexpression is often observed in many types of cancer (49) . Therefore, it is also possible YAP is one of the critical substrates of CDK1 that mediates CDK1-driven mitotic defects. There are several important questions need to be migration and invasion are critical processes for metastasis, which accounts for the majority of cancer-related deaths. YAP hyperphosphorylation induces supernumerary centrosomes (Fig. 5) and promotes migration and invasion (Fig. 6) . These data suggest a novel mechanism in which YAP promotes migration and invasion through centrosome amplification in a CDK1-phosphorylation dependent manner. YAP plays important roles in cancer development and metastasis in several types of cancer and remains as an attractive target for cancer therapy (3). We found that inhibition of CDK1 activity substantially impaired YAP-driven migration and invasion (Fig. 6F, G) . Since Rroscovitine (Selicilib) has been in phase I clinical trials with low toxicity (51), our findings support the feasibility of using CDK1 inhibitors in human cancers especially for those in which the Hippo-YAP signaling is dysregulated.
Discussion
Upon treatment with anti-mitotic agents, one of the prominent responses of the Hippo pathway is the marked increase in the phosphorylation of YAP (Fig. 1) and KIBRA (23) . MCF-7 cells (Fig. 1A and data not shown) , suggesting that the mitotic activation of Mst and Lats is cell-type specific. Lats2 was also phosphorylated by Aurora-A at the centrosomes during mitosis (53). YAP is a direct substrate of Lats1/2 (10, 12, 13) and KIBRA associates with Lats1/2 (25). Interestingly, CDK1 also phosphorylates KIBRA (24) and Lats1 (30) during mitosis, and one question is whether or how KIBRA/Lats1/2 is involved in the regulation of mitotic phosphorylation of YAP. Furthermore, YAP and TAZ are paralogs and have similar and distinct functions (2, 4) . We also found that TAZ is up-shifted upon Taxol or nocodazole treatment (Fig. 1A) . While all three phosphorylation sites on YAP are conserved in vertebrates, however, surprisingly, none of the phosphorylation sites of YAP exists on TAZ. We are currently investigating how TAZ is regulated and whether TAZ also plays a role in mitosis similar to YAP. 
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